Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

Fulgent Genetics (FLGT) reported robust Q2 2025 results, with core revenue of $81.7 million, marking a 16% year-over-year and 11% sequential increase, alongside a positive non-GAAP EPS of $0.07. Growth was broad-based across laboratory services, notably Precision Diagnostics (+7% sequentially) and Anatomic Pathology (+11% sequentially), supported by expanded sales efforts and new managed care contracts, including with the VA. Strategically, FLGT acquired ANP Technologies to bolster its therapeutic pipeline (FID-007 in Phase II, FID-022 in Phase I) and launched an enhanced whole genome sequencing service, while securing CE Mark for its exome testing to facilitate European market entry. Consequently, the company raised its full-year 2025 revenue guidance to $310-$320 million and improved its non-GAAP EPS outlook to a loss of $0.35 per share, though GAAP EPS guidance was revised to a larger loss of $2.10 due to a one-time impairment, with a strong cash position of $777.5 million maintained.

Analysis

Fulgent Genetics reported a strong second quarter for 2025, demonstrating significant momentum in its core laboratory services business and progress in its therapeutic pipeline. Core revenue reached $81.7 million, a 16% year-over-year and 11% sequential increase, prompting an upgrade in full-year revenue guidance to $310-$320 million. This growth was broad-based, with Anatomic Pathology up 11% and Biopharma Services up 54% sequentially, driven by an expanded sales organization and the addition of over 35 million covered lives through more than 20 new managed care agreements. Operationally, the company is realizing efficiencies, with non-GAAP gross margin improving to 44.2% and a positive non-GAAP EPS of $0.07. A GAAP loss of $19 million was reported, but this was heavily impacted by a one-time $9.9 million non-cash impairment charge. Strategically, Fulgent is advancing on multiple fronts: it launched an enhanced whole genome sequencing service with integrated RNA analysis, received a CE Mark to enter the European market with its exome test, and acquired ANP Technologies for approximately $4 million to secure proprietary nano drug delivery technology for its clinical candidates, FID-007 and FID-022. The balance sheet remains robust with $777.5 million in cash and equivalents, supporting an active share repurchase program and strategic investments with a controlled cash burn.

Key Decisions for Investors

• Investors should note the accelerating organic growth in the core laboratory business, which, combined with improved non-GAAP profitability, suggests the operational turnaround is gaining traction and supports the increased full-year guidance.
• The acquisition of ANP Technologies de-risks the therapeutic pipeline by bringing key intellectual property in-house; the completion of FID-007 enrollment by year-end and the subsequent data readout in 2026 are key catalysts to monitor for long-term value creation.
• Given the strong cash position of $777.5 million, an active share repurchase program, and positive non-GAAP earnings, investors should evaluate whether the market is fully pricing in both the core business execution and the long-term optionality of the therapeutics division.
• Consider monitoring key execution risks, including the pace of market penetration in Europe following the CE Mark approval, the ramp-up of the Foundation Medicine partnership, and potential seasonality in the Anatomic Pathology business in the second half of the year.